Rahul R Aggarwal, MD

Offices

2 locations · University of California San Francisco · UCSF Medical Group Business Services

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Aggarwal’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Imperial Courage Plan (HMO)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026
Imperial Dynamic Plan (HMO)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026
Imperial Senior Value (HMO C-SNP)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026

California Medical Board record

Licence A102876 · Current

Licensed to practise in California · since 2008 · expires 2027-12-31 · Northwestern University Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at UCSF Medical Center

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	4.9 (3.79 to 6.02) · 7,590 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	12.8 (11.3 to 14.4) · 2,019 cases	Worse	Jan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	139.4 (110.22 to 168.58) · 452 cases	Better	Jul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.622	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.626	Better	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.491	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.8 (0.7 to 1) · 2,336 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.24 (0.58 to 1.9) · 4,689 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	1.05 (0.89 to 1.2)	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.9 · 89 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	7.5 · 85 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	10.1 · 132 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.6 · 454 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 618 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	9.6 · 380 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.7 · 5,000 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.22 (0.06 to 0.38) · 15,965 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.2 (0.05 to 0.35) · 17,859 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.85 (0 to 1.83) · 4,184 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2 (1.1 to 2.9) · 6,516 cases	No different	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	7.35 (4.49 to 10.21) · 3,989 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5 (3.22 to 6.77) · 4,087 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.95 (0.74 to 3.15) · 2,034 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.95 (0.63 to 1.28) · 15,431 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	4 · 399 cases	None	Apr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.899	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.689	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	1.224	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16 · 156 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20 · 564 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	60.3 · 160 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-9.7 · 550 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	44.1 · 660 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.8 · 667 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.7 (4.8 to 6.7) · 2,019 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	6 · 421 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	10.5 · 53 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	20 · 107 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	13.9 (11.3 to 17.1) · 3,247 cases	No different	Jan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at UCSF Medical Center

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at UCSF Medical Center

Room was "always" clean	71%
Nurses "always" communicated well	80%
Doctors "always" communicated well	80%
Staff "always" explained	61%
Yes, staff "did" give patients this information	88%
Yes, staff "did" give patients information about help after discharge	87%
Doctors "always" explained things so they could understand	74%
Doctors "always" listened carefully	78%
Doctors "always" treated them with courtesy and respect	86%
Patients who gave a rating of "9" or "10" (high)	76%
Staff "always" explained new medications	75%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	78%
Nurses "always" treated them with courtesy and respect	86%
"Always" quiet at night	50%
"YES", patients would definitely recommend the hospital	81%
Staff "always" explained possible side effects	46%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$154,140

Medicare paid this office $154,140 for 246 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	126	$21,768	$82
Long return visit (40+ min)	74	$18,541	$128
Leuprolide acetate (for depot suspension), 7.5 mg	11	$10,079	None
Short return visit (20+ min)	89	$5,637	$49
New patient visit (45+ min)	29	$3,080	$106

See all 9 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	126	$21,768	$82
Long return visit (40+ min)	74	$18,541	$128
Leuprolide acetate (for depot suspension), 7.5 mg	11	$10,079	None
Short return visit (20+ min)	89	$5,637	$49
New patient visit (45+ min)	29	$3,080	$106
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	96	$2,592	$15
New patient visit (60+ min)	14	$2,254	$161
Telephone medical discussion with physician, 11-20 minutes	15	$1,053	$59
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle	13	$927	$33

Who their Medicare patients are

246 Original Medicare patients in 2024. Average age 75 · Women 5% · Also on Medicaid 9% · Health risk score 2.76. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: Cancer 75% · High blood pressure 68% · Coronary heart disease 27% · Chronic kidney disease 25% · Atrial fibrillation 22% · Diabetes 20% · Depression 17% · Heart failure 14% · Stroke 11% · COPD 7%.

The office billed $1,634,266, Medicare allowed $196,827 and paid $154,140; for 4,922 services of 34 kinds; $94,489 of it was for drugs given in the office and $59,650 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	246	4,922	75	2.76	$1,634,266	$154,140
2023	257	4,888	75	2.64	$2,311,106	$208,826
2022	278	2,582	74	2.46	$937,450	$112,137
2021	275	990	74	2.40	$591,127	$87,355
2020	246	794	74	2.28	$466,088	$59,113
2019	228	663	74	2.37	$510,526	$61,584
2018	226	543	73	2.25	$405,988	$51,199
2017	192	577	73	2.50	$420,153	$57,247
2016	212	643	72	2.32	$451,616	$63,054
2015	181	461	72	2.25	$323,698	$45,707
2014	147	373	71	2.11	$265,205	$37,353
2013	80	153	74	1.79	$113,311	$16,926

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 10 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	155	$28,414	$81
Leuprolide acetate (for depot suspension), 7.5 mg	15	$13,645	None
Short return visit (20+ min)	133	$12,174	$58
Long return visit (40+ min)	50	$9,555	$129
New patient visit (45+ min)	23	$2,743	$119
New patient visit (60+ min)	18	$2,595	$144
Telephone medical discussion with physician, 11-20 minutes	19	$1,185	$52
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle	15	$1,060	$33
Telephone medical discussion with physician, 5-10 minutes	21	$851	$32
Insertion of needle into vein for collection of blood sample	13	$412	$8

2022: 6 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	184	$40,151	$81
Long return visit (40+ min)	89	$20,012	$124
New patient visit (60+ min)	49	$7,936	$162
Short return visit (20+ min)	65	$4,247	$56
Telephone medical discussion with physician, 11-20 minutes	35	$3,012	$54
Insertion of needle into vein for collection of blood sample	11	$127	$3

2021: 7 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	175	$39,943	$84
Long return visit (40+ min)	105	$22,419	$121
New patient visit (60+ min)	45	$7,334	$163
Short return visit (20+ min)	61	$4,057	$50
Telephone medical discussion with physician, 21-30 minutes	32	$4,006	$79
Telephone medical discussion with physician, 11-20 minutes	37	$3,280	$57
New patient visit (45+ min)	13	$1,357	$104

2020: 9 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	126	$28,335	$91
Return visit (30+ min)	114	$14,223	$69
New patient visit (60+ min)	24	$3,284	$137
Telephone medical discussion with physician, 21-30 minutes	33	$3,223	$70
Short return visit (20+ min)	59	$3,102	$45
Telephone medical discussion with physician, 11-20 minutes	32	$2,271	$45
New patient visit (45+ min)	20	$2,218	$111
Return visit (30+ min)	11	$839	$76
New patient visit (30+ min)	12	$819	$68

2019: 3 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	195	$52,255	$94
New patient visit (60+ min)	36	$5,430	$151
Return visit (30+ min)	25	$3,276	$67

2018: 3 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	175	$40,422	$92
New patient visit (60+ min)	59	$8,045	$136
Return visit (30+ min)	23	$2,096	$64

2017: 3 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	144	$45,082	$94
New patient visit (60+ min)	79	$11,081	$140
Return visit (30+ min)	11	$924	$62

2016: 3 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	123	$41,079	$96
New patient visit (60+ min)	98	$13,989	$143
Return visit (30+ min)	44	$6,202	$68

2015: 3 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	102	$28,944	$95
New patient visit (60+ min)	73	$10,559	$145
Return visit (30+ min)	38	$3,524	$66

2014: 3 services

Sort by

Original Medicare services billed in 2014

Long return visit (40+ min)	85	$23,864	$94
New patient visit (60+ min)	63	$9,191	$146
Return visit (30+ min)	23	$2,647	$65

2013: 2 services

Sort by

Original Medicare services billed in 2013

Long return visit (40+ min)	50	$9,659	$96
New patient visit (60+ min)	47	$6,822	$145

Medicaid work

$2,767 in 2022

Medicaid paid $2,767 for 32 billed services this clinician did in 2022, up to 16 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2022

Long return visit (40+ min)	18	$2,107
Telehealth originating site facility fee	14	$659

Sort by

Medicaid work by year

2022	32	2	16	$2,767
2021	14	1	13	$1,441

See the largest Medicaid services in earlier years

2021

Sort by

Largest Medicaid services in 2021

Long return visit (40+ min)	14	$1,441

Drugs they prescribed that Part D paid

$1,467,417

Pharmacies billed $1,467,417 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

200 generic and fewer than 11 brand-name prescriptions · $1,467,417 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Xtandi	36	$475,065	$13,196
Erleada	18	$269,687	$14,983
Nubeqa	18	$217,263	$12,070
Abiraterone Acetate	49	$64,463	$1,316
Orgovyx	24	$64,375	$2,682

See all 6 drugs

Sort by

Every Part D drug this clinician prescribed

Xtandi	36	$475,065	$13,196
Erleada	18	$269,687	$14,983
Nubeqa	18	$217,263	$12,070
Abiraterone Acetate	49	$64,463	$1,316
Orgovyx	24	$64,375	$2,682
Prednisone	51	$339	$7

Year by year

Sort by

Part D prescribing by year

2024	332	76	None	None	$1,467,417
2023	525	95	4% (20)	None	$2,028,845
2022	756	105	2% (13)	None	$2,465,818
2021	616	94	4% (23)	29%	$1,893,872
2020	530	87	3% (15)	30%	$1,432,670
2019	676	102	3% (22)	25%	$1,501,174
2018	600	96	2% (14)	None	$2,027,784
2017	577	82	4% (20)	26%	$1,230,426
2016	482	66	8% (38)	19%	$509,110
2015	471	55	6% (26)	None	$872,355
2014	355	52	6% (20)	None	$375,373
2013	86	32	15% (13)	None	$25,504

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 10 drugs

Sort by

Part D drugs prescribed in 2023

Erleada	29	$429,597	$14,814
Nubeqa	32	$369,355	$11,542
Lenvima	13	$351,226	$27,017
Xtandi	23	$250,553	$10,894
Abiraterone Acetate	98	$86,480	$882
Orgovyx	28	$73,287	$2,617
Prednisone	89	$772	$9
Dexamethasone	23	$501	$22
Alendronate	22	$239	$11
Ondansetron	12	$127	$11

2022: 14 drugs

Sort by

Part D drugs prescribed in 2022

Xtandi	76	$919,810	$12,103
Erleada	40	$585,011	$14,625
Cabometyx	19	$418,719	$22,038
Abiraterone Acetate	163	$218,748	$1,342
Orgovyx	54	$136,431	$2,527
Nubeqa	15	$111,064	$7,404
Prednisone	116	$876	$8
Dexamethasone	28	$766	$27
Ondansetron	19	$402	$21
Levothyroxine	19	$355	$19
Gabapentin	19	$265	$14
Omeprazole	18	$199	$11
Tamsulosin	14	$141	$10
Alendronate	32	$112	$4

2021: 15 drugs

Sort by

Part D drugs prescribed in 2021

Xtandi	52	$566,139	$10,887
Cabometyx	25	$547,889	$21,916
Erleada	29	$394,475	$13,603
Abiraterone Acetate	102	$134,124	$1,315
Orgovyx	29	$67,198	$2,317
Prednisone	107	$732	$7
Dexamethasone	19	$455	$24
Levothyroxine	14	$428	$31
Ondansetron	15	$374	$25
Tamsulosin	13	$207	$16
Metformin Hcl Er	11	$190	$17
Alendronate	25	$179	$7
Omeprazole	15	$169	$11
Gabapentin	14	$133	$9
Benazepril	11	$68	$6

2020: 9 drugs

Sort by

Part D drugs prescribed in 2020

Cabometyx	19	$390,408	$20,548
Xtandi	35	$364,564	$10,416
Lynparza	13	$185,693	$14,284
Abiraterone Acetate	66	$166,468	$2,522
Prednisone	111	$746	$7
Dexamethasone	31	$708	$23
Tamsulosin	22	$543	$25
Levothyroxine	12	$314	$26
Omeprazole	15	$243	$16

2019: 15 drugs

Sort by

Part D drugs prescribed in 2019

Abiraterone Acetate	75	$476,449	$6,353
Xtandi	28	$330,222	$11,794
Cabometyx	12	$240,758	$20,063
Zytiga	15	$173,081	$11,539
Inlyta	11	$118,618	$10,783
Savaysa	13	$4,883	$376
Prednisone	162	$1,079	$7
Ondansetron	34	$787	$23
Dexamethasone	30	$630	$21
Bicalutamide	13	$406	$31
Alendronate	24	$325	$14
Levothyroxine	18	$212	$12
Omeprazole	25	$206	$8
Amlodipine Besylate	22	$168	$8
Prochlorperazine Maleate	15	$144	$10

2018: 12 drugs

Sort by

Part D drugs prescribed in 2018

Zytiga	118	$1,245,933	$10,559
Xtandi	26	$344,253	$13,241
Cabometyx	20	$340,232	$17,012
Prednisone	144	$1,132	$8
Bicalutamide	35	$899	$26
Levothyroxine	23	$473	$21
Dexamethasone	21	$430	$20
Tamsulosin	12	$397	$33
Alendronate	40	$349	$9
Ondansetron	17	$307	$18
Potassium Chloride	17	$277	$16
Venlafaxine Hcl Er	14	$203	$14

2017: 12 drugs

Sort by

Part D drugs prescribed in 2017

Zytiga	63	$588,612	$9,343
Cabometyx	19	$299,055	$15,740
Xtandi	29	$285,544	$9,846
Bicalutamide	85	$1,791	$21
Prednisone	79	$743	$9
Levothyroxine	24	$545	$23
Alendronate	53	$369	$7
Ondansetron	17	$190	$11
Amlodipine Besylate	24	$177	$7
Dexamethasone	14	$151	$11
Venlafaxine Hcl Er	11	$125	$11
Omeprazole	12	$86	$7

2016: 12 drugs

Sort by

Part D drugs prescribed in 2016

Zytiga	42	$326,382	$7,771
Xtandi	13	$108,919	$8,378
Fragmin	14	$50,944	$3,639
Bicalutamide	69	$1,956	$28
Prednisone	63	$640	$10
Ondansetron	17	$604	$36
Levothyroxine	21	$516	$25
Oxycodone	15	$441	$29
Dexamethasone	24	$208	$9
Alendronate	33	$155	$5
Omeprazole	22	$114	$5
Lisinopril	12	$64	$5

2015: 11 drugs

Sort by

Part D drugs prescribed in 2015

Zytiga	67	$511,847	$7,640
Xtandi	16	$139,810	$8,738
Votrient	11	$87,405	$7,946
Bicalutamide	42	$1,164	$28
Levothyroxine	23	$561	$24
Ondansetron	11	$535	$49
Prednisone	56	$463	$8
Dexamethasone	19	$324	$17
Omeprazole	18	$227	$13
Amlodipine Besylate	12	$104	$9
Alendronate	24	$81	$3

2014: 10 drugs

Sort by

Part D drugs prescribed in 2014

Votrient	19	$130,696	$6,879
Zytiga	15	$111,868	$7,458
Xtandi	13	$109,078	$8,391
Bicalutamide	54	$1,906	$35
Venlafaxine	13	$460	$35
Ondansetron	11	$416	$38
Levothyroxine	33	$403	$12
Prednisone	22	$180	$8
Dexamethasone	12	$163	$14
Alendronate	27	$146	$5

2013: 1 drug

Sort by

Part D drugs prescribed in 2013

Bicalutamide	12	$524	$44

Money from drug and device companies

$31,005 in 2025

Sort by

Industry payments by year

2025	7	23	$26,165	$31,005
2024	3	5	$8,225	$8,257
2023	8	21	$28,952	$30,842
2022	3	3	$5,529	$5,529
2021	6	19	$21,852	$22,693
2020	5	5	$6,568	$6,581
2019	4	13	$10,500	$11,591

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Merck Sharp & Dohme	None	$8,731	9 payments Consulting · 2025-11-17 · $7,040 Travel · 2025-11-17 · $150 Meals · 2025-11-06 · $35 Meals · 2025-11-06 · $50 Meals · 2025-11-06 · $50 Travel · 2025-11-06 · $234 Travel · 2025-11-06 · $123 Travel · 2025-11-05 · $820 Travel · 2025-11-05 · $229
Genentech	Columvi	$8,650	3 payments Consulting for Columvi · 2025-06-05 · $5,740 Meals for Columvi · 2025-06-05 · $74 Travel for Columvi · 2025-06-05 · $2,836
Novartis Pharmaceuticals	Pluvicto	$4,725	3 payments Consulting for Pluvicto · 2025-11-26 · $1,050 Consulting for Pluvicto · 2025-11-18 · $2,800 Consulting · 2025-04-30 · $875
Daiichi Sankyo	None	$3,870	2 payments Consulting · 2025-10-15 · $1,613 Consulting · 2025-02-13 · $2,258
F. Hoffmann-La Roche AG	None	$2,889	3 payments Meals · 2025-11-13 · $19 Consulting · 2025-11-13 · $2,460 Consulting · 2025-05-15 · $410
Janssen Scientific Affairs	Erleada	$2,038	2 payments Consulting for Erleada · 2025-07-01 · $1,920 Meals for Erleada · 2025-06-03 · $118

See all 23 published payments

Sort by

Every published payment

Novartis Pharmaceuticals	Consulting · 2025-11-26	Pluvicto	$1,050
Novartis Pharmaceuticals	Consulting · 2025-11-18	Pluvicto	$2,800
Merck Sharp & Dohme	Consulting · 2025-11-17	None	$7,040
Merck Sharp & Dohme	Travel · 2025-11-17	None	$150
F. Hoffmann-La Roche AG	Meals · 2025-11-13	None	$19
F. Hoffmann-La Roche AG	Consulting · 2025-11-13	None	$2,460
Merck Sharp & Dohme	Meals · 2025-11-06	None	$35
Merck Sharp & Dohme	Meals · 2025-11-06	None	$50
Merck Sharp & Dohme	Meals · 2025-11-06	None	$50
Merck Sharp & Dohme	Travel · 2025-11-06	None	$234
Merck Sharp & Dohme	Travel · 2025-11-06	None	$123
Merck Sharp & Dohme	Travel · 2025-11-05	None	$820
Merck Sharp & Dohme	Travel · 2025-11-05	None	$229
Daiichi Sankyo	Consulting · 2025-10-15	None	$1,613
Janssen Scientific Affairs	Consulting · 2025-07-01	Erleada	$1,920
Genentech	Consulting · 2025-06-05	Columvi	$5,740
Genentech	Meals · 2025-06-05	Columvi	$74
Genentech	Travel · 2025-06-05	Columvi	$2,836
Janssen Scientific Affairs	Meals · 2025-06-03	Erleada	$118
F. Hoffmann-La Roche AG	Consulting · 2025-05-15	None	$410
Novartis Pharmaceuticals	Consulting · 2025-04-30	None	$875
AstraZeneca Pharmaceuticals LP	Meals · 2025-02-24	Lynparza	$102
Daiichi Sankyo	Consulting · 2025-02-13	None	$2,258

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $8,257

Sort by

Payments by company in 2024

Janssen Research & Development	None	$4,082	3 payments Consulting · 2024-10-29 · $4,050 Meals · 2024-09-13 · $11 Meals · 2024-09-13 · $21
Abbvie	None	$2,175	1 payment Consulting · 2024-08-19 · $2,175
Merck Sharp & Dohme	None	$2,000	1 payment Consulting · 2024-05-09 · $2,000

2023: $30,842

Sort by

Payments by company in 2023

Merck Sharp & Dohme	Lynparza	$10,215	8 payments Travel · 2023-12-13 · $150 Consulting · 2023-12-13 · $6,100 Meals for Lynparza · 2023-12-08 · $35 Meals for Lynparza · 2023-12-08 · $50 Meals for Lynparza · 2023-12-08 · $50 Travel for Lynparza · 2023-12-07 · $1,058 Travel for Lynparza · 2023-12-07 · $333 Consulting · 2023-03-06 · $2,440
Genentech	Polivy	$6,000	2 payments Consulting · 2023-06-08 · $3,000 Consulting for Polivy · 2023-02-17 · $3,000
Janssen Global Services	Erleada	$4,794	3 payments Consulting for Erleada · 2023-10-12 · $675 Consulting for Erleada · 2023-06-16 · $4,050 Meals for Erleada · 2023-06-01 · $69
Novartis Pharmaceuticals	Pluvicto	$3,617	2 payments Consulting for Pluvicto · 2023-02-15 · $3,525 Meals for Pluvicto · 2023-02-15 · $92
AstraZeneca Pharmaceuticals LP	None	$2,660	1 payment Consulting · 2023-10-23 · $2,660
Amgen	None	$2,000	3 payments Meals · 2023-10-28 · $28 Meals · 2023-10-27 · $25 Consulting · 2023-02-24 · $1,947
Janssen Research & Development	None	$1,000	1 payment Consulting · 2023-11-21 · $1,000
AstraZeneca UK	None	$555	1 payment Consulting · 2023-03-14 · $555

2022: $5,529

Sort by

Payments by company in 2022

Bayer HealthCare Pharmaceuticals	Nubeqa	$2,855	1 payment Consulting for Nubeqa · 2022-03-12 · $2,855
Merck Sharp & Dohme	None	$2,135	1 payment Consulting · 2022-02-25 · $2,135
TerSera Therapeutics	None	$539	1 payment Consulting · 2022-08-13 · $539

2021: $22,693

Sort by

Payments by company in 2021

Pfizer	None	$7,765	4 payments Honoraria · 2021-11-09 · $2,100 Honoraria · 2021-07-27 · $1,665 Honoraria · 2021-04-13 · $1,000 Honoraria · 2021-04-06 · $3,000
Merck Sharp & Dohme	None	$4,880	1 payment Consulting · 2021-12-13 · $4,880
Exelixis	Cabometyx	$4,801	10 payments Paid to speak or teach for Cabometyx · 2021-12-10 · $3,960 Travel for Cabometyx · 2021-11-18 · $145 Travel for Cabometyx · 2021-11-18 · $190 Meals for Cabometyx · 2021-11-18 · $35 Meals for Cabometyx · 2021-11-18 · $23 Meals for Cabometyx · 2021-11-18 · $23 Meals for Cabometyx · 2021-11-18 · $66 Travel for Cabometyx · 2021-11-17 · $65 Travel for Cabometyx · 2021-11-17 · $148 Travel for Cabometyx · 2021-11-17 · $145
Merck Sharp & Dohme	None	$2,000	1 payment Consulting · 2021-08-25 · $2,000
Amgen	None	$1,947	1 payment Consulting · 2021-05-12 · $1,947
Jubilant Therapeutics	None	$1,300	2 payments Consulting · 2021-10-05 · $1,000 Consulting · 2021-08-03 · $300

2020: $6,581

Sort by

Payments by company in 2020

AstraZeneca Pharmaceuticals LP	Lynparza	$2,328	1 payment Consulting for Lynparza · 2020-10-07 · $2,328
Dendreon Pharmaceuticals	Provenge	$1,750	1 payment Consulting for Provenge · 2020-10-24 · $1,750
Clovis Oncology	Rubraca	$1,500	1 payment Consulting for Rubraca · 2020-09-01 · $1,500
Advanced Accelerator Applications	Lutathera	$990	1 payment Consulting for Lutathera · 2020-07-07 · $990
Pfizer	Inlyta	$13	1 payment Education for Inlyta · 2020-10-12 · $13

2019: $11,591

Sort by

Payments by company in 2019

Merck Sharp & Dohme	None	$6,333	7 payments Travel · 2019-09-09 · $150 Consulting · 2019-09-09 · $5,500 Meals · 2019-08-17 · $30 Meals · 2019-08-17 · $57 Meals · 2019-08-17 · $60 Travel · 2019-08-16 · $243 Travel · 2019-08-16 · $293
Clovis Oncology	Rubraca	$2,000	1 payment Consulting for Rubraca · 2019-03-05 · $2,000
Janssen Research & Development	None	$1,806	2 payments Consulting · 2019-12-12 · $1,750 Meals · 2019-10-23 · $56
Dendreon Pharmaceuticals	Provenge	$1,452	3 payments Consulting for Provenge · 2019-12-10 · $1,250 Meals for Provenge · 2019-12-09 · $124 Meals for Provenge · 2019-12-09 · $78

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Merck Sharp & Dohme LLC · Enhancing Sensitivity To Immune Checkpoint and Androgen Receptor Blockade in Small Cell Neuroendocrine and Intermediate Atypical Prostate Cancer With Bet Bromodomain Inhibition A Phase 2 Study · 2022	Their institution	$2,917,413
Merck Sharp & Dohme LLC · A Phase 2 Study of Pembrolizumab Plus 177lu-Psma-617 in Patients With Metastatic Castration Resistant Prostate Cancer · 2025	Their institution	$2,124,719
AstraZeneca Pharmaceuticals LP · Phase II Trial of the Efficacy of Azd6738 Alone and in Combination With Olaparib in Patients With Baf250a-Deficient Or Baf250a-Expressing Selected Solid Tumor Malignancies. · 2024	Their institution	$1,945,325
Merck Sharp & Dohme Corporation · Immunogenic Priming With Psma-Targeted Radioligand Therapy in Advanced Prostate Cancer A Phase 1b Study of 177lu-Psma-617 in Combination With Pembrolizumab · 2020	Their institution	$1,367,205
Merck Sharp & Dohme Corporation · Enhancing Sensitivity To Immune Checkpoint and Androgen Receptor Blockade in Small Cell Neuroendocrine and Intermediate Atypical Prostate Cancer With Bet Bromodomain Inhibition A Phase 2 Study · 2021	Their institution	$1,269,898
AstraZeneca Pharmaceuticals LP · Phase II Trial of the Efficacy of Azd6738 Alone and in Combination With Olaparib in Patients With Baf250a-Deficient Or Baf250a-Expressing Selected Solid Tumor Malignancies. · 2025	Their institution	$1,215,181
Merck Sharp & Dohme Corporation · Immunogenic Priming With Psma-Targeted Radioligand Therapy in Advanced Prostate Cancer A Phase 1b Study of 177lu-Psma-617 in Combination With Pembrolizumab · 2021	Their institution	$1,212,189
Merck Sharp & Dohme LLC · Enhancing Sensitivity To Immune Checkpoint and Androgen Receptor Blockade in Small Cell Neuroendocrine and Intermediate Atypical Prostate Cancer With Bet Bromodomain Inhibition# A Phase 2 Study · 2023	Their institution	$999,396
Merck Sharp & Dohme LLC · Immunogenic Priming With Psma-Targeted Radioligand Therapy in Advanced Prostate Cancer A Phase 1b Study of 177lu-Psma-617 in Combination With Pembrolizumab · 2022	Their institution	$989,965
Merck Sharp & Dohme LLC · Study Name#A Phase 2 Study of Bet Bromodomain Inhibitor Zen-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer · 2024	Their institution	$799,918
Amgen Inc. · Amg 509 Prostate Cancer 20180146. · 2024	Their institution	$758,477
Merck Sharp & Dohme LLC · Study Name#A Phase 2 Study of Pembrolizumab Plus 177lu-Psma-617 in Patients With Metastatic Castration Resistant Prostate Cancer · 2024	Their institution	$730,259
Novartis Pharmaceuticals Corporation · A Phase Ib and Or II Study of Lee001 in Combination With Docetaxel in Metastatic Castration Resistant Prostate Cancer · 2019	Their institution	$716,128
Janssen Research & Development, LLC · A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study To Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Arx517 As Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer · 2025	Their institution	$682,157
AstraZeneca Pharmaceuticals LP · Phase II Trial of the Efficacy of Azd6738 Alone and in Combination With Olaparib in Patients With Baf250a-Deficient Or Baf250a-Expressing Selected Solid Tumor Malignancies. · 2019	Their institution	$644,298
Janssen Research & Development, LLC · A Phase 1 First in Human Dose Escalation Study of Jnj63898081 in Subjects With Advanced Stage Solid Tumors · 2021	Their institution	$410,828
Merck Sharp & Dohme LLC · A Phase 2 Study of Bet Bromodomain Inhibitor Zen-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer · 2025	Their institution	$358,809
Janssen Research & Development, LLC · 2024	Their institution	$324,804
Amgen Inc. · A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Amg 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer · 2025	Their institution	$307,721
AstraZeneca Pharmaceuticals LP · Phase II Trial of the Efficacy of Azd6738 Alone and in Combination With Olaparib in Patients With Baf250a-Deficient Or Baf250a-Expressing Selected Solid Tumor Malignancies. · 2023	Their institution	$306,213
AstraZeneca UK Limited · This Is A Modular, Phase 2a, Open-Label, Multicentre Study of Ddr Agents (Or Combinations), Administered To Participants With Advanced/Metastatic Solid and/Or Haematological Malignancies With Molecular Alterations · 2023	Their institution	$268,856
Merck Sharp & Dohme LLC · A Phase 2 Study of Pembrolizumab Plus 177lu-Psma-617 in Patients With Metastatic Castration Resistant Prostate Cancer · 2023	Their institution	$250,000
Merck Sharp & Dohme Corporation · Immunogenic Priming With Psma-Targeted Radioligand Therapy in Advanced Prostate Cancer A Phase 1b Study of 177lu-Psma-617 in Combination With Pembrolizumab · 2019	Their institution	$238,094
Amgen Inc. · Evaluation of Target Expression and T Cell Redirecting Antibody Activity in Prostate Cancer · 2020	Their institution	$183,582
Amgen Inc. · Evaluation of Target Expression and T Cell Redirecting Antibody Activity in Prostate Cancer · 2024	Their institution	$183,582
ABBVIE INC. · A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of Abbv-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer · 2025	Their institution	$170,447
Novartis Pharmaceuticals Corporation · A Phase Ib and Or II Study of Lee001 in Combination With Docetaxel in Metastatic Castration Resistant Prostate Cancer · 2021	Their institution	$160,920
Merck Sharp & Dohme LLC · A Phase 2 Study of Pembrolizumab Plus 177lu-Psma-617 in Patients With Metastatic Castration Resistant Prostate Cancer · 2024	Their institution	$150,000
Janssen Research & Development, LLC · The Role of Highly Selective Androgen Receptor (Ar) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer · 2019	Their institution	$144,343
Janssen Research & Development, LLC · A Randomized Phase II Study of Apalutamide + Stereotactic Body Radiotherapy Sbrt in Castration Resistant Prostate Cancer Patients With Oligometastatic Disease on Psmapet Imaging · 2022	Their institution	$134,273
Amgen Inc. · Amg 160 Ph1b Master Protocol Evaluating Amg 160 in Subjects With Mcrpc 20190505 · 2024	Their institution	$121,696
BioXcel Therapeutics, Inc. · A Trial of Bxcl701 and Pembrolizumab in Patients With Mcrpc Either Small Cell Neuroendocrine Prostate Cancer Or Adenocarcinoma Phenotype · 2024	Their institution	$120,574
Novartis Pharmaceuticals Corporation · A Phase Ib and Or II Study of Lee001 in Combination With Docetaxel in Metastatic Castration Resistant Prostate Cancer · 2020	Their institution	$119,577
AstraZeneca Pharmaceuticals LP · Phase II Trial of the Efficacy of Azd6738 Alone and in Combination With Olaparib in Patients With Baf250a-Deficient Or Baf250a-Expressing Selected Solid Tumor Malignancies. · 2020	Their institution	$94,680
Janssen Research & Development, LLC · A Randomized Phase II Study of Apalutamide + Stereotactic Body Radiotherapy Sbrt in Castration Resistant Prostate Cancer Patients With Oligometastatic Disease on Psmapet Imaging · 2024	Their institution	$82,712
Janssen Research & Development, LLC · A Randomized Phase II Study of Apalutamide + Stereotactic Body Radiotherapy Sbrt in Castration Resistant Prostate Cancer Patients With Oligometastatic Disease on Psmapet Imaging · 2023	Their institution	$81,485
Amgen Inc. · Tarlatamab Ph1b/2 R/R Nepc. · 2022	Their institution	$78,884
Janssen Research & Development, LLC · A Randomized Phase II Study of Apalutamide + Stereotactic Body Radiotherapy Sbrt in Castration Resistant Prostate Cancer Patients With Oligometastatic Disease on Psmapet Imaging · 2021	Their institution	$78,268
Gilead Sciences, Inc. · A Phase 1b/2 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gs-5829 As A Single Agent and in Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer · 2020	Their institution	$76,901
Amgen Inc. · Tarlatamab Ph1b/2 R/R Nepc. · 2023	Their institution	$70,727
Janssen Research & Development, LLC · A Randomized Phase II Study of Apalutamide + Stereotactic Body Radiotherapy Sbrt in Castration Resistant Prostate Cancer Patients With Oligometastatic Disease on Psmapet Imaging · 2025	Their institution	$67,280
ABBVIE INC. · A Study To Assess Adverse Events, and How Intravenously (IV) Infused Abbv-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer · 2024	Their institution	$62,682
Janssen Research & Development, LLC · Aggarwal A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment - Emergent Small Cell Neuroendocrine Prostate Cancer · 2023	Their institution	$62,652
BioXcel Therapeutics, Inc. · Bxcl-701-201 · 2025	Their institution	$53,488
Janssen Research & Development, LLC · A Randomized Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (Sbrt) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on Psma-Pet Imaging · 2020	Their institution	$52,420
Deciphera Pharmaceuticals Inc. · A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of Dcc-3084 As Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors Driven By the Mapk Pathway · 2024	Their institution	$51,924
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl092 in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2025	Their institution	$50,774
MACROGENICS, INC. · A Phase 1 1b Dose Escalation and Cohort Expansion Study of Mgc018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors · 2024	Their institution	$44,900
Clovis Oncology, Inc. · A Phase 1/2, Multicenter, Open-Label, Non-Randomized Study To Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177lu-Fap-2286 in Patients With An Advanced Solid Tumor · 2022	Their institution	$43,568
Janssen Research & Development, LLC · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Arn-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer · 2019	Their institution	$37,635
Amgen Inc. · Amg 160 Ph1b Master Protocol Evaluating Amg 160 in Subjects With Mcrpc 20190505 · 2021	Their institution	$33,868
Janssen Research & Development, LLC · An Open-Label, Multicenter, Phase 1b Study of Jnj-63723283, A Pd-1 Inhibitor, Administered in Combination With Apalutamide in Subjects With Metastatic Castration Resistant Prostate Cancer · 2020	Their institution	$33,605
AstraZeneca UK Limited · This Is A Modular, Phase 2a, Open-Label, Multicentre Study of Ddr Agents (Or Combinations), Administered To Participants With Advanced/Metastatic Solid and/Or Haematological Malignancies With Molecular Alterations · 2022	Their institution	$32,026
AstraZeneca UK Limited · This Is A Modular, Phase 2a, Open-Label, Multicentre Study of Ddr Agents (Or Combinations), Administered To Participants With Advanced/Metastatic Solid and/Or Haematological Malignancies With Molecular Alterations · 2024	Their institution	$29,873
BioXcel Therapeutics, Inc. · A Trial of Bxcl701 and Pembrolizumab in Patients With Mcrpc Either Small Cell Neuroendocrine Prostate Cancer Or Adenocarcinoma Phenotype. · 2023	Their institution	$24,427
Amgen Inc. · A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-Like Protein 3 Half-Life Extended Bispecific T-Cell Engager Amg 757 in Subjects With De Novo Or Treatment Emergent Neuroendocrine Prostate Cancer · 2025	Their institution	$24,392
Deciphera Pharmaceuticals Inc. · A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of Dcc-3084 As Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors Driven By the Mapk Pathway · 2025	Their institution	$23,995
Astellas Pharma Global Development · A Multicenter, Open-Label Treatment Protocol of Gilteritinib (Asp2215) in Patients With Fms-Like Tyrosine Kinase 3 (Flt3) Mutated Relapsed Or Refractory Acute Myeloid Leukemia (Aml) Or Flt3-Mutated Aml in Complete Remission (Cr) With Minimal Residual Disease (Mrd) · 2020	Their institution	$23,793
Janssen Research & Development, LLC · A Phase 1 First in Human Dose Escalation Study of Jnj63898081 in Subjects With Advanced Stage Solid Tumors · 2022	Their institution	$23,421
Clovis Oncology, Inc. · A Study of Rucaparib Versus Physician'S Choice of Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton3) · 2019	Their institution	$23,358
Janssen Research & Development, LLC · A Phase 1b Study of Epi-7386, An Inhibitor of the Androgen Receptor N-Terminaldomain, in Combination With Abiraterone Acetate Plus Prednisone,Or Apalutamide Inmetastatic Castration-Resistant Prostate Cancer (Mcrpc) · 2022	Their institution	$22,118
Janssen Research & Development, LLC · A Phase 1, First-in-Human, Dose Escalation Study of Jnj-63898081 in Subjects With Advanced Stage Solid Tumors · 2020	Their institution	$21,546
Novartis Pharmaceuticals Corporation · A Phase Ib and Or II Study of Lee001 in Combination With Docetaxel in Metastatic Castration Resistant Prostate Cancer · 2022	Their institution	$17,200
SANOFI US SERVICES INC. · A Dose Escalation Study in Solid Tumors and A Dose Expansion Study of Prn1371 in Adult Patients With Metastatic Urothelial Carcinoma · 2022	Their institution	$15,100
Janssen Research & Development, LLC · A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment - Emergent Small Cell Neuroendocrine Prostate Cancer · 2022	Their institution	$14,921
BioNTech SE · 2025	Their institution	$11,706
Janssen Research & Development, LLC · A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment - Emergent Small Cell Neuroendocrine Prostate Cancer · 2024	Their institution	$10,585
Amgen Inc. · Tarlatamab Ph1b/2 R/R Nepc · 2021	Their institution	$9,626
Amgen Inc. · A Phase 3, Open-Label, Multicenter, Randomized Study of Xaluritamig Vs Cabazitaxel Or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy · 2025	Their institution	$9,038
Gilead Sciences, Inc. · A Phase 1b/2 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gs-5829 As A Single Agent and in Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer · 2019	Their institution	$6,488
Amgen Inc. · Amg 509 Prostate Cancer 20180146. · 2023	Their institution	$5,880
Janssen Research & Development, LLC · A Randomized Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (Sbrt) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on Psma-Pet Imaging · 2019	Their institution	$5,719
Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2024	This clinician	$5,421
Janssen Research & Development, LLC · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Arn-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer · 2020	Their institution	$5,225
Amgen Inc. · Amg 509 Prostate Cancer 20180146. · 2022	Their institution	$4,422
AstraZeneca Pharmaceuticals LP · Phase II Trial of the Efficacy of Azd6738 Alone and in Combination With Olaparib in Patients With Baf250a-Deficient Or Baf250a-Expressing Selected Solid Tumor Malignancies. · 2021	Their institution	$4,179
Amgen Inc. · Amg 509 Prostate Cancer 20180146. · 2020	Their institution	$2,131
Amgen Inc. · Amg 509 Prostate Cancer 20180146. · 2021	Their institution	$1,800
Amgen Inc. · Amg 160 Ph1b Master Protocol Evaluating Amg 160 in Subjects With Mcrpc 20190505 · 2023	Their institution	$778
Amgen Inc. · Tarlatamab Ph1b/2 R/R Nepc. · 2024	Their institution	$724
Amgen Inc. · Amg 160 Ph1b Master Protocol Evaluating Amg 160 in Subjects With Mcrpc 20190505 · 2022	Their institution	$453
Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2025	This clinician	$238
Novartis Pharmaceuticals Corporation · A Phase II, Open-Label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177lu) Vipivotide Tetraxetan (Aaa617) and Androgen Receptor Pathway Inhibitor (Arpi) Vs. Lutetium (177lu) Vipivotide Tetraxetan (Aaa617) in First-Line Treatment · 2025	Their institution	$203

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 75.0 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1174794309
Licence: CA A102876California A102876: Current · expires 2027-12-31
Trained: Northwestern University Feinberg Medical School, 2006
Group: University of California San Francisco · UCSF Medical Group Business Services
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: Yes
Taxonomy: Internal medicine (207R00000X)
Mailing address: 505 Parnassus Ave, Room M987, San Francisco, CA, 94143
NPI first listed: 2008-03-15
NPI last updated: 2008-03-15

This is when the NPI record was last certified, not a medical board exam.